Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination

International Journal of Neuropsychopharmacology

Volumn 17, Issue 3, 2014, Pages 371-381

  Hysek, Cédric M ^a   Simmler, Linda D ^a   Schillinger, Nathalie ^a   Meyer, Nicole ^a   Schmid, Yasmin ^a   Donzelli, Massimiliano ^a   Grouzmann, Eric ^b   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Dopamine; Emotion recognition; MDMA; Methylphenidate; Pharmacokinetic

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; METHYLPHENIDATE; PLACEBO;

ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CROSSOVER PROCEDURE; DRUG HALF LIFE; EMOTION; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; XEROSTOMIA;

ADULT; AFFECT; AREA UNDER CURVE; AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENDOCRINE SYSTEM; FEMALE; HALLUCINOGENS; HUMANS; MALE; METHYLPHENIDATE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; YOUNG ADULT;

EID: 84897845046     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001132     Document Type: Article

References (44)

1. Allwood MJ, Cobbold AF, Ginsburg J (1963) Peripheral vascular effects of noradrenaline, isopropylnoradrenaline and dopamine. Br Med Bull 19:132-136.
2. Bedi G, Hyman D, de Wit H (2010) Is ecstasy an 'empathogen'? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 68:1134-1140.
3. Blardi P, de Lalla A, Auteri A, Iapichino S, Dell'Erba A, Castrogiovanni P (2005) Plasma catecholamine levels after fluoxetine treatment in depressive patients. Neuropsychobiology 51:72-76.
4. Bourke C, Douglas K, Porter R (2010) Processing of facial emotion expression in major depression: a review. Aust N Z J Psychiatry 44:681-696.
5. Collins SL, Levin FR, Foltin RW, Kleber HD, Evans SM (2006) Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend 82:158-167.
6. de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farre M (2012) MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relvant? Front Genet 3:1-6.
7. Dumont GJ, Verkes RJ (2006) A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20:176-187.
8. Dunand M, Gubian D, Stauffer M, Abid KA, Grouzmann E (2013) High throughput and sensitive quantitation of plasma catecholamines by ultraperformance liquid chromatography-tandem mass spectrometry using a solid phase microwell extraction plate. Anal Chem 85:3539-3544.
9. Eisenhofer G, Rundquist B, Aneman A, Friberg P, Dakak N, Kopin IJ, Jacobs MC, Lenders JW (1995) Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 80:3009-3017.
10. Fantegrossi WE, Bauzo RM, Manvich DM, Morales JC, Votaw JR, Goodman MM, Howell LL (2009) Role of dopamine transporters in the behavioural effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. Psychopharmacol (Berl) 205:337-347.
11. Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, O'Mathuna B, Segura M, de la Torre R (2007) Pharmacological interaction between 3,4- methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323:954-962.
12. Han DD, Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6:6.
13. Hariri AR, Mattay VS, Tessitore A, Fera F, Smith WG, Weinberger DR (2002) Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacol 27:1036-1040.
14. Hysek CM, Liechti ME (2012) Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacol (Berl) 224:363-376.
15. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Clin Pharmacol Ther 90:246-255.
16. Hysek CM, Domes G, Liechti ME (2012a) MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. Psychopharmacol (Berl) 222:293-302.
17. Hysek CM, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, Liechti ME (2012b) Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol 166:2277-2288.
18. Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, Liechti ME (2012c) Effects of the α2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4- methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340:286-294.
19. Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Hoener MC, Liechti ME (2012d) Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE 7:e36476. doi: 10.1371/journal.pone.0036476.
20. Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME (2013) α-Adrenergic receptors contribute to the acute effects of MDMA in humans. J Clin Psychopharmacol 33:658-666.
21. Janke W, Debus G (1978) Die Eigenschaftswörterliste. Göttingen: Hogrefe.
22. Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX (2012) Psilocybin biases facial recognition, goal-directed behaviour, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 72:898-906.
23. Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037.
24. Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14:269-274.
25. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacol 22:513-521.
26. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioural effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258.
27. McCabe SE, Knight JR, Teter CJ, Wechsler H (2005) Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 100:96-106.
28. Newton TF, Roache JD, De La Garza R II, , Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R (2006) Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacol 31:1537-1544.
29. Ross RG (2006) Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 163:1149-1152.
30. Rothman RB, Baumann MH, Blough BE, Jacobson AE, Rice KC, Partilla JS (2010) Evidence for noncompetitive modulation of substrate-induced serotonin release. Synapse 64:862-869.
31. Schmeichel BE, Berridge CW (2013) Neurocircuitry underlying the preferential sensitivity of prefrontal catecholamines to low-dose psychostimulants. Neuropsychopharmacol 38:1079-1084.
32. Seifritz E, Baumann P, Muller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F, Holsboer-Trachsler E (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. a placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacol 14:253-263.
33. Sommers DK, van Wyk M, Snyman JR (1994) Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine. Eur J Clin Pharmacol 46:441-444.
34. Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE 5:e12412. doi: 10.1371/journal. pone.0012412.
35. Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, Bosron WF (2004) Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 310:469-476.
36. Upadhyaya HP, Brady KT, Liao J, Sethuraman G, Middaugh L, Wharton M, Sallee FR (2003) Neuroendocrine and behavioural responses to dopaminergic agonists in adolescents with alcohol abuse. Psychopharmacol (Berl) 166:95-101.
37. Verrico CD, Miller GM, Madras BK (2007) MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacol 189:489-503.
38. Verrico CD, Lynch L, Fahey MA, Fryer AK, Miller GM, Madras BK (2008) MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. J Psychopharmacol 22:187-202.
39. Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, Zhu W, Swanson JM (2003) Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacol (Berl) 166:264-270.
40. Wardle MC, Garner MJ, Munafo MR, de Wit H (2012) Amphetamine as a social drug: effects of d-amphetamine on social processing and behaviour. Psychopharmacol (Berl) 223:199-210.
41. Weizman R, Dick J, Gil-Ad I, Weitz R, Tyano S, Laron Z (1987) Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity. Life Sci 40:2247-2252.
42. Wilkins C, Sweetsur P, Griffiths R (2011) Recent trends in pharmaceutical drug use among frequent injecting drug users, frequent methamphetamine users and frequent ecstasy users in New Zealand, 2006-2009. Drug Alcohol Rev 30:255-263.
43. Winhusen T, Somoza E, Singal BM, Harrer J, Apparaju S, Mezinskis J, Desai P, Elkashef A, Chiang CN, Horn P (2006) Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol Biochem Behav 85: 29-38.
44. Zerssen DV (1976) Die Beschwerden-Liste. Münchener Informationssystem. München: Psychis.